A.W. Menzin
Hofstra University
11 Papers
28 Citations
A.W. Menzin is an academic researcher from Hofstra University. The author has contributed to research in topics: Cancer & Adjuvant therapy. The author has an hindex of 5, co-authored 11 publications.
Chat about Author
Papers
Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
Andrew Shih,A.W. Menzin,J.S. Whyte,J.L. Lovecchio,Anthony Liew,Houman Khalili,Tawfiqul Bhuiya,Peter K. Gregersen,Peter K. Gregersen,Annette Lee,Annette Lee +10 more
TL;DR: Differential gene expression shows myeloid lineage cells are the primary cell group expressing soluble factors in primary samples while fibroblasts do so in metastatic samples, and the proportion of these populations changes from primary to metastatic in a shift from mainly epithelial cells to leukocytes with few cancer epithelium cells in the metastases.
Metastatic Malignant Ovarian Steroid Cell Tumor: A Case Report and Review of the Literature
TL;DR: A 47-year-old female who presented with hirsutism, virilization, and amenorrhea and received three cycles of bleomycin, etoposide, and cisplatin and is now free of disease 24 months after surgery.
Toward the Quadruple Aim: Impact of a Humanistic Mentoring Program to Reduce Burnout and Foster Resilience
TL;DR: The MAP-IT program has shown effectiveness both in fostering resilience and a sense of personal accomplishment, and the time is ripe for institutional programming to create and foster the personal tools needed to prevent burnout and its sequelae.
12
Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience.
Aaron Nizam,Bethany Bustamante,Weiwei Shan,Karin K. Shih,J.S. Whyte,Antoinette Sakaris,Lisa dos Santos,Marina Frimer,A.W. Menzin,Alexander Truskinovsky,Gary L. Goldberg +10 more
- 22 Nov 2019
TL;DR: The majority of patients with CSO presented with advanced stage disease and received adjuvant platinum-based chemotherapy after cytoreductive surgery and the median overall survival of 23 months was not affected by the stage of the disease.
10
•Journal Article
Ovarian Sertoli-Leydig Cell Tumor with Predominant Heterologous Mucinous Differentiation and Foci of Hepatocytic Differentiation: Case Report and Review of The Literature
TL;DR: This was a very rare case of a 15-year old girl diagnosed with Sertoli-Leydig cell tumor with heterologous elements consisting predominantly of mucinous epithelium and a sparse Sertolian cell component, mimicking mucinous neoplasm, which created a challenge for pathologists, especially on frozen sections.
5